Gilead Sciences, Inc. v. Merck & Co, Inc. et al
Filing
254
ORDER APPROVING 229 JOINT PRETRIAL STATEMENT AND ORDER. Signed by Judge Beth Labson Freeman on 2/25/2016. (blflc3S, COURT STAFF) (Filed on 2/25/2016)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
John M. Farrell (CA Bar No. #99649)
farrell@fr.com
FISH & RICHARDSON P.C.
500 Arguello Street, Suite 500
Redwood City, CA 94063
Telephone: (650) 839-5070
Facsimile: (650) 839-5071
Jonathan E. Singer (CA Bar No. #187908)
singer@fr.com
FISH & RICHARDSON P.C.
3200 RBC Plaza
60 South Sixth Street
Minneapolis, MN 55402
Telephone: (612) 335-5070
Facsimile: (612) 288-9696
Attorneys for Plaintiff
GILEAD SCIENCES, INC.
Additional counsel listed on signature page
17
18
20
UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF CALIFORNIA
SAN JOSE DIVISION
21
22
GILEAD SCIENCES, INC.,
Plaintiff,
24
26
27
Joshua H. Lerner (SBN 220755)
jlerner@durietangri.com
Laura E. Miller (SBN 271713)
lmiller@duritangri.com
DURIE TANGRI LLP
217 Leidesdorff Street
San Francisco, CA 94111
Telephone: 415-362-6666
Facsimile: 415-236-6300
Attorneys for Defendants
MERCK & CO., INC., MERCK SHARP &
DOHME CORP. and ISIS
PHARMACEUTICALS, INC.
19
25
Bruce R. Genderson (Pro Hac Vice)
bgenderson@wc.com
Jessamyn S. Berniker (Pro Hac Vice)
jberniker@wc.com
Stanley E. Fisher (Pro Hac Vice)
sfisher@wc.com
WILLIAMS & CONNOLLY LLP
725 Twelfth Street, N.W.
Washington, D.C. 20005
Telephone: (202) 434-5000
Facsimile: (202) 434-5029
Juanita R. Brooks (CA Bar No. #75934)
brooks@fr.com
FISH & RICHARDSON P.C.
12390 El Camino Real
San Diego, CA 92130
Telephone: (858) 678-5070
Facsimile: (858) 678-5099
16
23
Stephen S. Rabinowitz
stephen.rabinowitz@hugheshubbard.com
Patrice P. Jean (Pro Hac Vice)
patrice.jean@hugheshubbard.com
Mitchell Epner (Pro Hac Vice)
mitchell.epner@hugheshubbard.com
HUGHES HUBBARD & REED LLP
One Battery Park Plaza
New York, NY 10004
Telephone: (212) 837-6000
Facsimile: (212) 299-6807
v.
Case No. 5:13-cv-04057-BLF/PSG
[PROPOSED] JOINT PRETRIAL
STATEMENT AND ORDER
MERCK & CO, INC., MERCK SHARP &
DOHME CORP. and ISIS
PHARMACEUTICALS, INC.,
Defendants
28
67988621_5
[PROPOSED] JOINT PRETRIAL STATEMENT AND ORDER
Case No. 5:13-cv-04057-BLF/PSG
1
2
3
I.
THE ACTION
A. Parties
Plaintiff Gilead Sciences, Inc. (“Plaintiff” or “Gilead”) and Defendants Merck & Co., Inc.
4
(“Merck & Co.”), Merck Sharp & Dohme Corp (“MSD Corp.”), and Ionis Pharmaceuticals, Inc.
5
(“Ionis”), formerly known as Isis Pharmaceuticals, Inc., (collectively, “Defendants” or “Merck”)
6
are the parties that will appear at trial.
7
8
9
B. Substance of the Action
Gilead manufactures and sells sofosbuvir, the active ingredient of orally administered
drugs prescribed for the treatment of chronic hepatitis C (“HCV”) infection. Merck & Co. is the
10
corporate parent of MSD Corp. MSD Corp. and Ionis are joint assignees of two patents: U.S.
11
Patent Nos. 7,105,499 (“the ’499 patent”) and 8,481,712 (“the ’712 patent”) (collectively, “Merck
12
Patents”), both titled “Nucleoside Derivatives as Inhibitors of RNA-Dependent RNA Viral
13
Polymerase.” On August 30, 2013, Gilead initiated this action for declaratory judgment pursuant
14
to 28 U.S.C. §§ 2201 and 2202. In its complaint, Gilead alleged that the manufacture, use, offer
15
for sale, and/or importation of sofosbuvir and the drug product that is the subject of the first
16
sofosbuvir NDA has not infringed, does not infringe, and would not, if marketed, infringe, directly
17
or indirectly, any valid claim of the ’499 or ’712 patents and that the ’499 and ’712 patents are
18
invalid. (ECF No. 1.) MSD Corp. and Ionis (collectively, “Counterclaimants”) asserted
19
counterclaims, seeking declaratory judgment that Gilead’s marketing of sofosbuvir, following
20
FDA approval, would induce and contribute to infringement of the ’499 and ’712 patents and
21
seeking compensatory damages for infringement arising from any commercial sale and offer for
22
sale of sofosbuvir by Gilead. (ECF Nos. 51, 62.) On December 6, 2013, the FDA approved
23
Gilead’s NDA 204671 for sofosbuvir (SOVALDI®) used in combination with other drugs as a
24
once daily oral therapy for chronic HCV infection. On October 10, 2014, the FDA approved
25
Gilead’s NDA 205834 for sofosbuvir used in combination with ledipasvir (HARVONI®) as a once
26
daily oral therapy for chronic HCV infection. Gilead makes, sells, and offers to sell sofosbuvir
27
(SOVALDI® and HARVONI®) in the United States for treatment of HCV infection. On
28
2
[PROPOSED] JOINT PRETRIAL STATEMENT AND ORDER
Case No. 5:13-cv-04057-BLF/PSG
1
November 28, 2014, the Counterclaimants filed amended and supplemental counterclaims seeking
2
a judgment that Gilead’s marketing of sofosbuvir induces and contributes to infringement of the
3
’499 and ’712 patents and seeking damages for infringement from Gilead’s commercial sale and
4
offer for sale of its sofosbuvir products. (ECF No. 98).
Counterclaimants contend that Gilead’s marketing and sale of SOVALDI® and
5
6
HARVONI® induces and contributes to direct infringement of claims 1 and 2 of the ’499 patent
7
and claims 1–3, 5, 7, and 9–11 of the ’712 patent by patients and caregivers who use these
8
products.1 Induced infringement under 35 U.S.C. §271(b) is present when a person actively
9
induces infringement of a patent, knowing of the patent and that the acts induced constitute
10
infringement. Contributory infringement under 35 U.S.C. § 271(c) is present when a person offers
11
to sell or sells within the United States a component of a patented manufacture or composition, or
12
a material for use in practicing a patented process, knowing the same to be especially made or
13
especially adapted for use in an infringement of such patent, and not a staple article or commodity
14
of commerce suitable for substantial noninfringing use. On February 1, 2016, this Court granted
15
summary judgment of infringement. (ECF No. 214).2 The Court further determined that, whether
16
the jury should be informed of this Court’s entry of judgement of infringement, and if so, how it
17
should be presented, are issues better left for the final pretrial conference. (ECF No. 214).
18
19
Gilead alleges that each of the asserted claims of the patents-in-suit are invalid on the
following grounds:3
20
The asserted claims of the ’499 patent and the ’712 patent are invalid for failure to
21
meet the enablement requirement of 35 U.S.C. § 112, ¶ 1. Gilead’s position is that, a
22
patent’s description of the claimed invention must be sufficiently full and clear to
23
1
24
25
2
26
27
28
3
Defendants’ infringement allegations are found in their Second Amended and Supplemental
Counterclaims (ECF No. 98) and in their Amended Disclosure of Asserted Claims and
Infringement Contentions, served on Gilead on June 6, 2016.
Gilead objects to the Court’s claim construction of the term “administering” in the claims of
the ’499 patent (ECF No. 140), and reserves the right to appeal or otherwise contest that
construction in further proceedings in this litigation. The Court adopted the parties’ agreed
construction of the term “compound” as used in the asserted claims of the ’712 patent.
Gilead’s invalidity defenses are found in its Complaint, (ECF No. 1, ¶¶ 68, 76), and in
Gilead’s Amended Invalidity Contentions, served on Defendants on June 16, 2015.
3
[PROPOSED] JOINT PRETRIAL STATEMENT AND ORDER
Case No. 5:13-cv-04057-BLF/PSG
1
enable a person of ordinary skill in the field at the time of filing to make and use the
2
full scope of the claimed invention, and must disclose a practical utility for the claimed
3
invention. Merck’s position is that a patent’s description of the claimed invention must
4
be sufficiently full and clear as to enable a person of ordinary skill in the field at the
5
time of filing to practice the claimed invention, and must disclose a practical utility for
6
the claimed invention. Gilead contends that the asserted claims of the Merck Patents
7
fail to satisfy the “how-to-make,” “how-to-use,” and practical utility subconditions of
8
the enablement requirement.
9
The asserted claims of the ’499 patent and the ’712 patent are invalid for failure to
10
meet the written description requirement of 35 U.S.C. § 112, ¶ 1. To satisfy the written
11
description requirement, the applicant must reasonably convey to those skilled in the
12
art that, as of the priority date, he or she was in possession of the claimed invention.
13
The asserted claims of the ’499 patent and the ’712 patent are invalid for derivation and
14
lack of inventorship under 35 U.S.C. § 102(f) and (g). Under § 102(f), a person is not
15
entitled to a patent if “he did not himself invent the subject matter sought to be
16
patented.” Under § 102(g), a person is not entitled to a patent if, before the person’s
17
invention thereof, the invention was made in this country by another inventor who had
18
not abandoned, suppressed, or concealed it.
19
The asserted claims of the ’499 patent and the ’712 patent are invalid as anticipated by
20
U.S. Patent Application Publication No. 2005/0009737 (“Clark”), under 35 U.S.C. §
21
102, to the extent the claims are not entitled to a priority date before Clark published on
22
January 13, 2005. For a claim to be invalid as anticipated, all of its requirements must
23
have existed in a single device or method that predates the claimed invention, or must
24
have been described in a single previous publication or patent that predates the claimed
25
invention.
26
27
28
The asserted claims of the ’712 patent are invalid as anticipated by Sofia et al.,
“Discovery of a β-D-2’Deoxy-2’-α-fluoro-2’-β-C-methyluridine Nucleotide Prodrug
4
[PROPOSED] JOINT PRETRIAL STATEMENT AND ORDER
Case No. 5:13-cv-04057-BLF/PSG
1
(PSI-7977) for the Treatment of Hepatitis C Virus,” J. Med. Chem., 53:7202–7218
2
(2010) (“Sofia”), under 35 U.S.C. § 102, to the extent the claims are not entitled to a
3
priority date before Sofia published on September 16, 2010. For the claim to be invalid
4
as anticipated, all of its requirements must have existed in a single device or method
5
that predates the claimed invention, or must have been described in a single previous
6
publication or patent that predates the claimed invention.
7
The asserted claims of the ’499 patent are invalid as indefinite under 35 U.S.C. § 112,
8
¶ 2. A claim is invalid for indefiniteness if its language, when read in light of the
9
specification and the prosecution history, fails to inform, with reasonable certainty,
10
those skilled in the art about the scope of the claimed invention.
11
Merck denies Gilead’s allegations of invalidity, and asserts that Gilead cannot meet its burden of
12
proving by clear and convincing evidence that the asserted claims of the patents-in-suit are invalid.
13
Merck also asserts that some of these invalidity grounds are not cognizable in this case as a matter
14
of law.
15
As identified in its Answer to Defendants’ Amended Counterclaims, (ECF No. 67), Gilead
16
also asserts equitable defenses to the counterclaims of infringement. These equitable defenses as
17
asserted by Gilead are:
18
Laches. Laches requires that (a) the patentee’s delay in bringing suit was unreasonable
19
and inexcusable, and (b) the alleged infringer suffered material prejudice attributable to
20
the delay.
21
Waiver. Waiver requires that a patentholder, with full knowledge of the material facts,
22
intentionally relinquish its patent enforcement rights or act in a manner that is so
23
inconsistent with an intent to enforce its rights as to induce a reasonable belief that
24
such right has been relinquished.
25
Estoppel. Equitable estoppel requires that (a) the patentholder, through misleading
26
conduct, leads the alleged infringer to reasonably infer that the patentholder does not
27
intend to enforce its patent against the alleged infringer; (b) the alleged infringer relies
28
5
[PROPOSED] JOINT PRETRIAL STATEMENT AND ORDER
Case No. 5:13-cv-04057-BLF/PSG
1
on that conduct; and (c) due to its reliance, the alleged infringer will be materially
2
prejudiced if the patentee is allowed to proceed with its claim.
3
Unclean hands. A showing of unclean hands requires that one coming for relief have
4
committed some unconscionable act immediately and necessarily related to the equity
5
that he seeks in respect of the matter in litigation.
6
Merck denies these Gilead allegations and asserts that Gilead cannot meet its burden of proving
7
them. Merck also asserts that some of these equitable defenses are not cognizable in this case as a
8
matter of law.
9
10
11
12
C. Relief Sought
Gilead’s Position
Gilead seeks the following relief (described in its Complaint, ECF No. 1):
13
14
A declaration that the asserted claims of the ’499 patent and the ’712 patent are
invalid under 35 U.S.C. §§ 102 and/or 112.
A declaration that the asserted claims of the ’499 patent and the ’712 patent are
15
unenforceable against Gilead under the equitable doctrines of laches, waiver,
16
estoppel, and/or unclean hands.
17
18
19
A declaration that Gilead does not infringe any valid claim of the ’499 patent or the
’712 patent.
An injunction enjoining Defendants and their agents, representatives, attorneys,
20
employees, and those persons in active concert or participation with them who
21
receive actual notice herefrom from threatening or initiating infringement litigation
22
against Gilead or its customers, dealers, or suppliers, or any prospective or present
23
sellers, dealers, distributors or customers of Gilead, or charging them either orally
24
or in writing with infringement of the ’499 or ’712 patents.
25
A finding that Defendants are not entitled to any damages.
26
27
28
6
[PROPOSED] JOINT PRETRIAL STATEMENT AND ORDER
Case No. 5:13-cv-04057-BLF/PSG
1
A judgment that this is an “exceptional case” justifying the award of Gilead’s
2
reasonable attorneys’ fees, expenses, and costs in this action under 35 U.S.C. § 285
3
both until the time of trial and thereafter.
4
5
Merck’s Position
6
7
Merck seeks the following relief (described in the Second Amended and Supplemental
Counterclaims, ECF No. 98):
8
9
A judgment that Gilead’s commercial sale and offer for sale of sofosbuvir induces
and contributes to infringement of the ’499 patent and the ’712 patent.
10
11
An Order dismissing Gilead’s complaint with prejudice and entering judgment in
favor of Merck.
12
Damages adequate to compensate Merck for past infringement from Gilead’s
13
commercial sale and offer for sale of sofosbuvir, in the form of a reasonable royalty
14
on past U.S. sales of SOVALDI® and HARVONI® and including pre- and post-
15
judgment interest.
16
A reasonable royalty for Gilead’s ongoing and future infringement.
17
A judgment that this case is “exceptional” justifying an award of Merck’s
18
reasonable attorneys’ fees, expenses and costs under 35 U.S.C. § 285, both until the
19
time of trial and thereafter.
20
D. Federal Jurisdiction and Venue
21
The Parties agree that this Court has subject matter jurisdiction under 28 U.S.C. §§ 1331
22
and 1338. Personal jurisdiction and venue are not disputed.
23
II.
FACTUAL BASIS FOR ACTION
24
A.
Undisputed facts
25
1.
Gilead is a company organized and existing under the laws of the State of Delaware
26
with its principal place of business at 333 Lakeside Drive, Foster City, California 94404.
27
28
7
[PROPOSED] JOINT PRETRIAL STATEMENT AND ORDER
Case No. 5:13-cv-04057-BLF/PSG
1
2.
Merck & Co. is a company organized under the laws of the State of New Jersey
2
with its principal place of business at One Merck Drive, P.O. Box 100, Whitehouse Station, NJ
3
08889-0100.
4
3.
MSD Corp. is a company organized under the laws of the State of New Jersey with
5
its principal place of business at One Merck Drive, P.O. Box 100, Whitehouse Station, NJ 08889-
6
0100.
7
4.
MSD Corp. is a subsidiary of Merck & Co.
8
5.
Ionis is a company organized under the laws of the State of Delaware with its
9
principal place of business at 2855 Gazelle Court, Carlsbad, CA 92010.
10
6.
MSD Corp. and Ionis are co-owners of the ’499 patent.
11
7.
The ’499 patent issued on September 12, 2006.
12
8.
MSD Corp. and Ionis are the co-owners of the ’712 patent.
13
9.
The ’712 patent issued on July 9, 2013.
14
10.
In this action, Merck relies on a priority date of January 18, 2002 for the ’499 and
15
’712 patents.
16
17
11.
filed by Merck on January 18, 2002.
18
19
12.
22
23
24
25
All facts admitted to in the Requests For Admissions identified in Appendix D and
Appendix E to this pre-trial order.
20
21
The applications that ultimately issued as the ’499 and ’712 patents-in-suit were
13.
All facts admitted to in the Joint Stipulation filed September 29, 2015 (Dkt. No.
14.
All facts admitted to in the parties’ statements of undisputed facts in their summary
153).
judgment papers. (Dkt. Nos. 167-1 and 177-22).
B. Disputed Facts
Gilead’s Statement
26
27
28
8
[PROPOSED] JOINT PRETRIAL STATEMENT AND ORDER
Case No. 5:13-cv-04057-BLF/PSG
1
1.
Whether there is clear and convincing evidence that the inventions in each of the
2
asserted claims of the ’499 patent were derived from information disclosed to Merck by
3
Pharmasset regarding the work of Jeremy Clark.
4
2.
Whether there is clear and convincing evidence that the inventions in each of the
5
asserted claims of the ’712 patent were derived from information disclosed to Merck by
6
Pharmasset regarding the work of Jeremy Clark.
7
8
9
10
11
3.
Whether any delay by Merck in asserting the ’499 patent was unreasonable and
inexcusable and, if so, whether Gilead suffered a material prejudice as a result of any such delay.
4.
Whether any delay by Merck in asserting the ’712 patent was unreasonable and
inexcusable and, if so, whether Gilead suffered a material prejudice as a result of any such delay.
5.
Whether Merck’s conduct during its interactions with Pharmasset was misleading,
12
whether that misleading conduct led Pharmasset and Gilead to a reasonable belief that Merck did
13
not intend to assert any patent rights and, if so, whether Pharmasset and Gilead relied upon that
14
conduct and have suffered material prejudice as a result of that reliance.
15
6.
Whether there is clear and convincing evidence that the inventions claimed by the
16
’499 patent had first been made in the United States by Jeremy Clark, and whether Jeremy Clark
17
abandoned, suppressed, or concealed his invention.
18
7.
Whether there is clear and convincing evidence that, as of January 18, 2002, the
19
specification for the ’499 patent did not teach a person of ordinary skill in the art to make the
20
compounds and all of their prodrugs encompassed by the full scope of the asserted claims of the
21
’499 patent, without undue experimentation.
22
8.
Whether these is clear and convincing evidence that, as of January 18, 2002, the
23
specification for the’499 patent did not teach a person of ordinary skill in the art how to use the
24
compounds and all of their prodrugs encompassed by the full scope of the asserted claims of the
25
’499 patent, according to the method described by the asserted claims, without undue
26
experimentation.
27
28
9
[PROPOSED] JOINT PRETRIAL STATEMENT AND ORDER
Case No. 5:13-cv-04057-BLF/PSG
1
9.
Whether there is clear and convincing evidence that, as of January 18, 2002, the
2
specification for the ’499 patent did not disclose to a person of ordinary skill in the art a pratical
3
utility for using the compounds and all of their prodrugs encompassed by the full scope of the
4
asserted claims of the ’499 patent according to the method described by the asserted claims.
5
10.
Whether there is clear and convincing evidence that, as of January 18, 2002, the
6
specification for the ’499 patent did not disclose to a person of ordinary skill in the art that the
7
inventors of the ’499 patent had possession of a method of treating HCV infection by
8
administering the claimed genus of compounds and all possible prodrugs either alone or in
9
combination with the active agents listed in claim 2 of the ’499 patent.
10
11.
Whether there is clear and convincing evidence that the inventions claimed by the
11
’712 patent had first been made in the United States by Jeremy Clark, and whether Jeremy Clark
12
abandoned, suppressed, or concealed his invention.
13
12.
Whether there is clear and convincing evidence that, as of January 18, 2002, the
14
specification for the ’712 patent did not teach a person of ordinary skill in the art to make the
15
compounds encompassed by the full scope of the asserted claims of the ’712 patent, without undue
16
experimentation.
17
13.
Whether these is clear and convincing evidence that, as of January 18, 2002, the
18
specification for the ’712 patent did not teach a person of ordinary skill in the art how to use the
19
compounds encompassed by the full scope of the asserted claims of the ’712 patent without undue
20
experimentation.
21
14.
Whether there is clear and convincing evidence that, as of January 18, 2002, the
22
specification for the ’712 patent did not disclose to a person of ordinary skill in the art a pratical
23
utility for the compounds encompassed by the full scope of the asserted claims of the ’712 patent.
24
15.
Whether there is clear and convincing evidence that, as of January 18, 2002, the
25
specification for the ’712 patent did not disclose to a person of ordinary skill in the art that the
26
inventors of the ’712 patent had possession of the claimed compounds.
27
28
10
[PROPOSED] JOINT PRETRIAL STATEMENT AND ORDER
Case No. 5:13-cv-04057-BLF/PSG
1
16.
Whether Merck’s delay in asserting its patent rights or in making any claim of
2
rights to PSI-6130 or PSI-7977 amounted to a knowing relinquishment of its patent rights or
3
induced a reasonable belief in Gilead that such rights had been relinquished.
4
5
6
7
17.
If the ’499 patent is found to be valid and enforceable, the amount of the reasonable
royalty to which Merck is entitled.
18.
If the ’712 patent is found to be valid and enforceable, the amount of the reasonable
royalty to which Merck is entitled.
8
9
10
Merck’s Statement
19.
Whether there is clear and convincing evidence that a person of ordinary skill in the
11
art would not have been able to practice any of the asserted claims of the ’499 patent without
12
undue experimentation as of January 18, 2002.
13
20.
Whether there is clear and convincing evidence that the inventions in each of the
14
asserted claims of the ’499 patent had first been made in the United States by Jeremy Clark before
15
January 18, 2002, and whether Jeremy Clark abandoned, suppressed, or concealed any such
16
alleged invention.
17
21.
Whether there is clear and convincing evidence that the specification of the ’499
18
patent, as filed on January 18, 2002, does not convey to a person of ordinary skill in the art that
19
the inventors were in possession of the invention as claimed in any of the asserted claims of the
20
’499 patent.
21
22.
Whether there is clear and convincing evidence that, as of January 18, 2002, a
22
person of ordinary skill in the art would not have been able to practice any of the asserted claims
23
of the ’712 patent without undue experimentation.
24
23.
Whether there is clear and convincing evidence that the inventions in each of the
25
asserted claims of the ’712 patent had first been made in the United States by Jeremy Clark before
26
January 18, 2002, and whether Jeremy Clark abandoned, suppressed, or concealed any such
27
alleged invention.
28
11
[PROPOSED] JOINT PRETRIAL STATEMENT AND ORDER
Case No. 5:13-cv-04057-BLF/PSG
1
24.
Whether there is clear and convincing evidence that the specification of the ’712
2
patent, as filed on January 18, 2002, does not convey to a person of ordinary skill in the art that the
3
inventors were in possession of the invention as claimed in any of the asserted claims of the ’712
4
patent.
5
6
25.
the ’499 patent is not supported by a practical utility.
7
8
26.
27.
Whether Merck delayed in asserting the ’499 patent after Gilead’s infringement of
that patent had begun and Gilead suffered material prejudice as a result.
11
12
Whether there is clear and convincing evidence that each of the asserted claims of
the ’712 patent is not supported by a practical utility.
9
10
Whether there is clear and convincing evidence that each of the asserted claims of
28.
Whether Merck delayed in asserting the ’712 patent after Gilead’s infringement of
that patent had begun and Gilead suffered material prejudice as a result.
13
29.
Whether any delay by Merck in asserting its patent rights amounted to a knowing
14
and intentional relinquishment of its patent rights or was so inconsistent with an intent to enforce
15
its rights that it induced a reasonable belief in Gilead that such rights had been relinquished.
16
30.
The amount of the reasonable royalty to which Merck is entitled to compensate for
17
Gilead’s past, ongoing, and future infringement of the ’499 and ’712 patents.
18
III.
19
DISPUTED LEGAL AND EQUITABLE ISSUES
The parties are in agreement as to the disputed legal issues relevant to most claims and
20
defenses, and those agreed-to areas of dispute are listed in the “Joint Statement,” below. The
21
parties do not agree as to the disputed legal issues relevant to some of Gilead’s invalidity defenses
22
and, therefore, have included separate statements regarding those defenses.
23
Joint Statement
24
1.
25
Whether any of the asserted claims of the ’499 patent are entitled to a priority date
of January 18, 2002.
26
27
28
12
[PROPOSED] JOINT PRETRIAL STATEMENT AND ORDER
Case No. 5:13-cv-04057-BLF/PSG
1
2.
Whether Gilead can show by clear and convincing evidence that each of the
2
asserted claims of the ’499 patent is invalid under 35 U.S.C. § 112 for failure to disclose a
3
practical utility for the claimed methods.
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
3.
Whether Gilead can show by clear and convincing evidence that each of the
asserted claims of the ’499 patent is invalid under 35 U.S.C. § 112, for indefiniteness.
4.
Whether any of the asserted claims of the ’712 patent are entitled to a priority date
of January 18, 2002.
5.
Whether Gilead can show by clear and convincing evidence that each of the
asserted claims of the ’712 patent is invalid under 35 U.S.C. § 112 for failure to disclose a
practical utility for the claimed compounds.
6.
Whether Gilead can meet its burden of proving that Merck’s claims for
infringement are barred by the doctrine of laches.
7.
Whether Gilead can meet its burden of proving that Merck’s claims for
infringement are barred by the doctrine of waiver.
8.
Whether Gilead can meet its burden of proving that Merck’s claims for
infringement are barred by the doctrine of equitable estoppel.
9.
Whether Gilead can meet its burden of proving that Merck’s claims for
infringement are barred by the doctrine of unclean hands.
10.
Whether Gilead is entitled to an injunction enjoining Merck and its agents from
20
threatening or initiating infringement litigation against Gilead or its customers, dealers, or
21
suppliers or charging them either orally or in writing with infringement of the ’499 or ’712
22
patents.
23
24
25
26
11.
Whether Merck is entitled to an Order dismissing Gilead’s Complaint with
prejudice and entering judgment in favor of Defendants and Counterclaim Plaintiffs;
12.
Whether this is an exceptional case justifying the award of Gilead’s or Merck’s
reasonable attorneys’ fees, expenses, and costs in this action under § 285.
27
28
13
[PROPOSED] JOINT PRETRIAL STATEMENT AND ORDER
Case No. 5:13-cv-04057-BLF/PSG
1
13.
Whether Merck is entitled to any damages, including past damages and an ongoing
2
royalty, and, if so, the amount of damages.
3
Gilead’s Statement
4
14.
If any asserted claim of the ’499 patent is not entitled to a priority date of January
5
18, 2002, whether Gilead can show by clear and convincing evidence that it is invalid as
6
anticipated by Clark.
7
15.
Whether Gilead can show by clear and convincing evidence that each of the
8
asserted claims of the ’499 patent is invalid under 35 U.S.C. § 102(f) for being derived from the
9
invention of Jeremy Clark.
10
16.
Whether Gilead can show by clear and convincing evidence that each of the
11
asserted claims of the ’499 patent is invalid under 35 U.S.C. § 102(g) for having first been made in
12
the United States by Jeremy Clark, who did not abandon, suppress, or conceal his invention.
13
17.
Whether Gilead can show by clear and convincing evidence that each of the
14
asserted claims of the ’499 patent is invalid under 35 U.S.C. § 112 for failure to enable a person of
15
ordinary skill in the art to make the compounds and all of their possible prodrugs encompassed by
16
the asserted claims.
17
18.
Whether Gilead can show by clear and convincing evidence that each of the
18
asserted claims of the ’499 patent is invalid under 35 U.S.C. § 112 for failure to enable a person of
19
ordinary skill in the art to use the claimed methods.
20
19.
Whether Gilead can show by clear and convincing evidence that each of the
21
asserted claims of the ’499 patent is invalid under 35 U.S.C. § 112 for lacking a written
22
description of the claimed methods.
23
20.
Whether Gilead can show by clear and convincing evidence that each of the
24
asserted claims of the ’712 patent is invalid under 35 U.S.C. § 102(f) for being derived from the
25
invention of Jeremy Clark.
26
27
28
14
[PROPOSED] JOINT PRETRIAL STATEMENT AND ORDER
Case No. 5:13-cv-04057-BLF/PSG
1
21.
If any asserted claim of the ’712 patent is not entitled to a priority date of January
2
18, 2002, whether Gilead can show by clear and convincing evidence that it is invalid as
3
anticipated by Clark.
4
22.
If any asserted claim of the ’712 patent is not entitled to a priority date of January
5
18, 2002, whether Gilead can show by clear and convincing evidence that it is invalid as
6
anticipated by Sofia.
7
23.
Whether Gilead can show by clear and convincing evidence that each of the
8
asserted claims of the ’712 patent is invalid under 35 U.S.C. § 102(g) for having first been made in
9
the United States by Jeremy Clark, who did not abandon, suppress, or conceal his invention.
10
24.
Whether Gilead can show by clear and convincing evidence that each of the
11
asserted claims of the ’712 patent is invalid under 35 U.S.C. § 112 for failure to enable a person of
12
ordinary skill in the art to make the claimed compounds.
13
25.
Whether Gilead can show by clear and convincing evidence that each of the
14
asserted claimed of the ’712 patent is invalid under 35 U.S.C. § 112 for failure to enable a person
15
of ordinary skill in the art to use the claimed compounds.
16
26.
Whether Gilead can show by clear and convincing evidence that each of the
17
asserted claims of the ’712 patent is invalid under 35 U.S.C. § 112 for lacking a written
18
description of the claimed compounds.
19
20
21
27.
Whether Merck may rely on infringement by or mode of action of sofosbuvir as
evidence of practical utility for the asserted claims.
28.
Whether Merck may rely on sofosbuvir’s commercial success as evidence of
22
practical utility for the asserted claims.
23
Merck’s Statement
24
29.
Whether as a matter of law Gilead may assert that the asserted claims of the ’499
25
patent are invalid under 35 U.S.C. § 102(f) for being derived from the work of Jeremy Clark,
26
which post-dates Merck’s filing date of January 18, 2002.
27
28
15
[PROPOSED] JOINT PRETRIAL STATEMENT AND ORDER
Case No. 5:13-cv-04057-BLF/PSG
1
30.
Whether as a matter of law Gilead may assert that the asserted claims of the ‘’499
2
patent are invalid under 35 U.S.C. § 102(g) for alleged prior invention by Jeremy Clark, whose
3
alleged date of invention post-dates Merck’s filing date of January 18, 2002.
4
31.
Whether as a matter of law Gilead may assert that the asserted claims of the ’499
5
patent are invalid as anticipated by Clark, which was filed and was published after Merck’s filing
6
date of January 18, 2002.
7
32.
Whether as a matter of law Gilead may assert that the asserted claims of the ’499
8
patent are invalid as anticipated by Sofia, which was filed and was published after Merck’s filing
9
date of January 18, 2002.
10
33.
Whether Gilead can show by clear and convincing evidence that each of the
11
asserted claims of the ’499 patent is invalid under 35 U.S.C. § 112 for failure to enable a person of
12
skill in the art to practice the claimed invention.
13
34.
Whether as a matter of law Gilead may assert that the asserted claims of the ’712
14
patent are invalid under 35 U.S.C. § 102(f) for being derived from the work of Jeremy Clark,
15
which post-dates Merck’s filing date of January 18, 2002.
16
35.
Whether as a matter of law Gilead may assert that the asserted claims of the ‘712
17
patent are invalid under 35 U.S.C. § 102(g) for alleged prior invention by Jeremy Clark, whose
18
alleged date of invention post-dates Merck’s filing date of January 18, 2002.
19
36.
Whether as a matter of law Gilead may assert that the asserted claims of the ’712
20
patent are invalid as anticipated by Clark, which was filed and was published after Merck’s filing
21
date of January 18, 2002.
22
37.
Whether as a matter of law Gilead may assert that the asserted claims of the ’712
23
patent are invalid as anticipated by Sofia, which was filed and was published after Merck’s filing
24
date of January 18, 2002.
25
38.
Whether Gilead can show by clear and convincing evidence that each of the
26
asserted claims of the ’712 patent is invalid under 35 U.S.C. § 112 for failure to enable a person of
27
skill in the art to practice the claimed invention.
28
16
[PROPOSED] JOINT PRETRIAL STATEMENT AND ORDER
Case No. 5:13-cv-04057-BLF/PSG
1
IV.
ESTIMATE OF TRIAL TIME
2
The parties anticipate that trial will take two weeks.
3
The parties are in disagreement as to the order in which trial should proceed. It is Gilead’s
4
position that because this Court has entered judgment of infringement, the case should commence
5
with Gilead’s invalidity defense and that Gilead, as the party with the burden of proof, should
6
present first and should be permitted to present a rebuttal presentation on invalidity. It is also
7
Gilead’s position that because there is no liability for an invlaid claim, the issue of damages
8
should only be presented after liability. It is also Gilead’s position that it should be permitted to
9
call live or by deposition adverse witnesses during its case in chief regardless of whether Merck
10
intends to call the same witness live or by deposition during its case in chief.
11
It is Merck’s position that Merck should present first because it is the patentee and has the
12
burden of proof on damages. It is also Merck’s position that regardless of the order at trial, Merck
13
should be permitted to present a rebuttal case on damages. It is Merck’s position that deposition
14
testimony should not be presented at trial for any witness who is testifying live at trial. It is also
15
Merck’s position that if Gilead wishes to cross-examine a Merck witness it should be permitted to
16
do so only after that witness has testified on direct examination in Merck’s case, with the
17
understanding that such cross-examination need not be limited to the scope of the direct
18
examination. The reciprocal arrangement would apply to Merck’s cross-examination of Gilead’s
19
witnesses.
20
V.
TRIAL ALTERNATIVES AND OPTIONS
21
A.
22
Pursuant to the ADR L.R. 3-2 and 3-4(b), the parties stipulated to Private ADR in the form
Settlement Discussion
23
of direct discussions between the parties; the Court approved the parties’ stipulation. (ECF Nos.
24
64, 65.) The parties filed a Joint Notice of ADR Compliance on January 21, 2014, reporting that
25
Private ADR was conducted as stipulated and ordered. (ECF No. 70.) The parties were not able
26
to reach a resolution. Moreover, pursuant to the Court’s Jury Pretrial Standing Order, lead trial
27
counsel met and conferred on February 5, 2016 to discuss the possibility of settlement.
28
17
[PROPOSED] JOINT PRETRIAL STATEMENT AND ORDER
Case No. 5:13-cv-04057-BLF/PSG
1
B.
2
Neither Gilead nor Defendants have any proposed amendments to the pleadings. Neither
3
Gilead nor Defendants seek to dismiss any claims or counterclaims.
4
5
Amendments or Dismissals
C.
Bifurcation or Separate Trial of Issues
Indefiniteness
6
As described above, Gilead maintains that each of the asserted claims of the ’499 patent is
7
invalid as indefinite. The parties agree that claim indefiniteness is a matter of law for the Court’s
8
adjudication that turns on underlying facts. Gilead’s position is that while the evidence
9
concerning indefiniteness can be presented simultaneously with the other matters within the jury’s
10
purview, Gilead would move the Court to rule as a matter of law at the close of evidence If the
11
Court determines to adopt Merck’s position, Gilead asks that that ruling applies only to evidence
12
that is relevant exclusively to Gilead’s indefiniteness defense.
13
Merck’s position is that any evidence pertaining to this defense should be presented
14
outside the presence of the jury, and that the defense be reserved for resolution by the Court.
15
Gilead’s Equitable Defenses
16
Gilead proposes that these defenses be addressed in briefing following trial and that, if
17
there is a need for the Court to hear further evidence, that can also be discussed post-trial. If the
18
Court determines to adopt Merck’s position, Gilead asks that that ruling applies only to evidence
19
that is relevant exclusively to resolution of Gilead’s equitable defenses.
20
It is Merck’s view that any evidence pertaining to these defenses should be presented
21
outside the presence of the jury, and that these defenses be reserved for resolution by the Court.
22
VI.
23
APPENDICES TO PRETRIAL ORDER
The following Appendices are attached hereto:
24
Gilead’s Witness List
Appendix A
25
Defendants’ Witness List
Appendix B
26
Gilead’s Exhibit List (and objections)
Appendix C-2
27
Defendants’ Exhibit List (and objections)
Appendix C-3
28
18
[PROPOSED] JOINT PRETRIAL STATEMENT AND ORDER
Case No. 5:13-cv-04057-BLF/PSG
1
Gilead’s Discovery Responses
Appendix D-1
2
Gilead’s Deposition Designations (and
objections)
Defendants’ Discovery Responses
Appendix D-2
Defendants’ Deposition Designations (and
objections)
Appendix E-2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
VII.
Appendix E-1
STIPULATIONS
The following stipulations were agreed upon by the parties as discussed below, and are
made a part of this Pretrial Order.
A. Trial Exhibits & Demonstratives
1. The listing of a document on a party’s exhibit list is not an admission that such
document is relevant or admissible when offered by the opposing party for the
purpose that the opposing party wishes to admit the document. Each party reserves
the right to object to the relevancy or admissibility of any evidence offered by the
other party, at the time such evidence is offered, in view of the specific context in
which such evidence is offered.
2. The parties will each provide to each other’s counsel of record via email a list of
witnesses that it intends to call in Court, live or by deposition, by 7:00 p.m. two
calendar days before the witness will testify. For witnesses testifying by
deposition, each party will also provide a transcript (and video, if applicable) of
those portions of the deposition it intends to play.
3. Although the parties have made good-faith efforts to identify the sponsoring
witness or witnesses through which they expect to introduce exhibits at trial,
neither party is precluded from using or introducing an exhibit with a different
witness. Unless otherwise agreed to by the parties during trial, the parties will each
provide to each other’s counsel of record via e-mail a written list of exhibits, by
exhibit number, for each witness that it intends to call in Court by 7:00 p.m. two
calendar days before the day the witness will testify. Objections to any of the
19
[PROPOSED] JOINT PRETRIAL STATEMENT AND ORDER
Case No. 5:13-cv-04057-BLF/PSG
1
disclosed exhibits shall be made by no later than 7:00 p.m. the following day, and
2
the parties will meet and confer regarding any objections by 9:00 p.m. that same
3
evening.
4
4. The parties will provide, by e-mail, any demonstrative exhibits (in color as
5
applicable) they anticipate using on direct examination of a witness at trial to the
6
other party’s counsel of record. Gilead proposes that such an exchange occur no
7
later than 7:00 p.m. on the calendar day before the witness is called. Merck
8
proposes that such an exchange occur no later than 8:00 a.m. on the calendar day
9
before the witness is called. Any objections to demonstrative exhibits shall be
10
made by 9:00 p.m. that same day, and the parties shall meet and confer as soon as
11
possible thereafter to resolve such objections. Any disputes as to demonstrative
12
exhibits shall be raised with the Court as appropriate before trial resumes on the
13
day of their anticipated use.
14
15
16
17
18
19
20
5. Demonstrative exhibits exchanged will not be used by the opposing party prior to
being used by the disclosing party.
6. The parties agree that demonstrative exhibits that the parties intend to use at trial
need not be included on their respective lists of trial exhibits.
7. The Federal Judicial Center video entitled “The Patent Process: An Overview for
Jurors” will be shown to the jurors after jury selection, before opening arguments.
8. The foregoing notice provisions regarding demonstrative exhibits shall not apply to
21
demonstrative exhibits created in the courtroom during live testimony at trial or to
22
the enlargement, highlighting, ballooning, or excerpting of trial exhibits that have
23
been admitted in evidence or trial testimony. Mere enlargement, highlighting,
24
ballooning, or excerpting of trial exhibits admitted in evidence or trial testimony
25
does not create a demonstrative exhibit.
26
27
28
20
[PROPOSED] JOINT PRETRIAL STATEMENT AND ORDER
Case No. 5:13-cv-04057-BLF/PSG
1
2
VIII. BINDING EFFECT OF THE JOINT PRETRIAL STATEMENT AND ORDER
The foregoing admissions having been made by the parties, and the parties having
3
specified the foregoing issues of fact and law remaining to be litigated, this order shall
4
supplement the pleadings and govern the course of trial of this action, unless modified to prevent
5
manifest injustice.
6
7
Dated: February 11, 2016
FISH & RICHARDSON P.C.
8
By: /s/ Douglas E. McCann
Douglas E. McCann
9
10
Attorneys for Plaintiff
GILEAD SCIENCES, INC.
11
12
13
Dated: February 11, 2016
WILLIAMS & CONNOLLY LLP
14
15
By: /s/ Jessamyn Berniker
Jessamyn Berniker
Attorneys for Defendants
MERCK & CO., INC.; MERCK SHARP &
DOHME CORP.; ISIS PHARMACEUTICALS,
INC.
16
17
18
19
SIGNATURE ATTESTATION
20
21
22
Pursuant to Civil Local Rule 5.1(i)(3), I attest under penalty of perjury that concurrence in
the filing of this document has been obtained from its signatory
/s/ Doulas E. McCann
23
24
25
26
SO ORDERED
February 25, 2016
HONORABLE BETH LABSON FREEMAN
27
28
21
[PROPOSED] JOINT PRETRIAL STATEMENT AND ORDER
Case No. 5:13-cv-04057-BLF/PSG
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
Why Is My Information Online?